IP Library Patent Application 16418813
Patent Application
App. No. 16/418,813

METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
16/418,813
Abstract

The present invention relates to immunoglobulins that bind FcγRIIb+ cells and coengage the antigen on the cell's surface and an FcγRIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.

Claims (11)

1 - 20 . (canceled)

21 . A method of treating cancer in a patient in need of such treatment, comprising:

administering to the patient an anti-human CD40 antibody comprising a light chain and a heavy chain, the heavy chain comprising a human IgG1 Fc domain comprising a S267E amino acid substitution, wherein the numbering is according to the EU index as in Kabat.

22 . The method of claim 21 , wherein the cancer is pancreatic cancer.

23 . The method of claim 21 , comprising administering the anti-human CD40 antibody in combination with one or more chemotherapeutic agents.

24 . The method of claim 23 , wherein the chemotherapeutic agent is gemcitabine.

25 . The method of claim 24 , wherein the one or more chemotherapeutic agents are gemcitabine in combination with paclitaxel.

26 . The method of claim 24 , comprising administering the anti-human CD40 antibody in combination with a second antibody.

27 . The method of claim 25 , comprising administering the anti-human CD40 antibody in combination with a second antibody.

28 . A method of causing B cell proliferation in a patient comprising:

contacting the B cell of the patient with an anti-human CD40 antibody comprising amino acid substitution S267E in the Fc region as compared to a parent human IgG1 Fc region, wherein the numbering is according to the EU index as in Kabat thereby causing B cell proliferation in the patient.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 15, 2019
From: CHU, SEUNG YUP; DESJARLAIS, JOHN R.; KARKI, SHER BAHADUR; LAZAR, GREGORY ALAN; MOORE, GREGORY L.; VOSTIAR, IGOR
To: XENCOR, INC.
Reel/Frame 049756/0164 →